TEE
AXSM icon

Tibra Equities Europe’s Axsome Therapeutics AXSM Stock Holding History

Tibra Equities Europe’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,404
Closed -$319K – 261
2019
Q1 		$319K Buy
+22,404
New +$208K 0.03% 325

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Tibra Equities Europe's AXSM Position: Q2 2019 in Review

Tibra Equities Europe sold out of Axsome Therapeutics (AXSM) in Q2 2019, closing a stake of 22,404 shares — an estimated $319K sold.

Tibra Equities Europe first reported a position in AXSM in Q1 2019 and held it in 1 quarter. The position peaked at $319K in Q1 2019. 109 funds tracked by Wall St. Rank hold AXSM as of Q2 2019.

  • Tibra Equities Europe reported no remaining Axsome Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 22,404 Axsome Therapeutics shares in Q2 2019, an estimated $319K.
  • Tibra Equities Europe first reported a position in Axsome Therapeutics in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Axsome Therapeutics position peaked at $319K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.